Clinical trials: WHIM
Neutropenia
AMD 3100 for Treatment of Myelokathexis
This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and…
- Trial name
- NCT01058993
- Testing
- AMD3100 or plerixafor
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work in treating patients with pancreatic cancer that has spread to other places.
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02907099
- Testing
- CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
WHIM Syndrome
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants…
- Trial name
- NCT03005327
- Testing
- X4P-001
- Where
- 2 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- X4 Pharmaceuticals
Leukemia, Myeloid, Acute
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML.
- Trial name
- AMD3100+MEC (NCT00512252)
- Testing
- AMD3100, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Myelokathexis, Infections
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts
- Trial name
- NCT02231879
- Testing
- Plerixafor, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone.
- Trial name
- NCT00082329
- Testing
- AMD 3100 (Mozobil plerixafor), Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Solid Tumor
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory…
- Trial name
- NCT02737072
- Testing
- LY2510924, Durvalumab
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Hiv
Autologous CD4 T-Cells in HIV (C34-CXCR4)
A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in…
- Trial name
- NCT03020524
- Testing
- Autologous CD4 T-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Metastatic Pancreatic Cancer
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
- Trial name
- NCT04177810
- Testing
- Cemiplimab, Plerixafor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with…
- Trial name
- NCT02765165
- Testing
- USL311, Lomustine
- Where
- 6 sites in United States, Spain
- Volunteers
- 26 people
- Sponsor
- Proximagen, LLC
Lymphoma, Non-Hodgkin, Hodgkin Disease
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
This study will evaluate the safety and efficacy of intravenous AMD3100 added to a standard G-CSF mobilization regimen of patients undergoing autologous stem cell transplantation for lymphoma.
- Trial name
- NCT00733824
- Testing
- AMD3100, G-CSF, Apheresis
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Waldenstrom's Macroglobulinemia
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT03225716
- Testing
- Ulocuplumab, Ibrutinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute